Pelvic Evisceration, Radical Hysterectomy DRG

DRG 735 covers pelvic evisceration, radical hysterectomy, and radical vulvectomy cases without Major Complication or Comorbidity or Complication or Comorbidity and defines the clinical scope of high-complexity pelvic oncologic surgery. This Diagnosis-Related Group matters for inpatient reimbursement because procedure selection and documentation of comorbid conditions determine grouping and associated Medicare payment.

DRG 735 Overview

DRG 735 encompasses extensive pelvic oncologic resections including pelvic evisceration, radical hysterectomy, and radical vulvectomy performed without a Major Complication or Comorbidity and without a Complication or Comorbidity. These procedures are high-complexity, often multidisciplinary surgeries for advanced gynecologic malignancy or refractory pelvic disease. For Medicare payment, this Diagnosis-Related Group groups cases of comparable resource use and sets inpatient reimbursement parameters tied to the principal procedure and absence of higher-severity diagnoses. Accurate coding of procedures and comorbidity status determines assignment to this Diagnosis-Related Group and affects the hospital’s inpatient prospective payment.

Trials evaluating perioperative blood loss minimization and transfusion strategies for patients undergoing pelvic evisceration or radical hysterectomy: these studies test protocols such as enhanced intraoperative hemostatic techniques, restrictive transfusion thresholds, and use of cell salvage in a high-bleed, high-complexity surgical population primarily composed of patients with advanced gynecologic malignancies. The objective is to reduce intraoperative transfusions, complications, and length of stay; results inform surgeons and hospital administrators about best practices to lower complication-related costs and resource use.
Comparative effectiveness studies of different surgical approaches and perioperative care pathways in radical vulvectomy and radical hysterectomy: randomized or prospective cohort studies compare open versus minimally invasive techniques where applicable, extent of lymphadenectomy, or standardized enhanced recovery after surgery (ERAS) pathways in patients without major comorbidities (no CC/MCC). These trials address which approaches yield lower complication rates, faster functional recovery, and shorter hospitalization, providing evidence that influences DRG-level resource utilization, coding, and payer coverage decisions.
Post-discharge and survivorship outcomes research focusing on functional recovery, wound complications, and quality of life after pelvic exenteration-type procedures: longitudinal observational studies and registry-based research follow patients after discharge to quantify rates of readmission, wound breakdown, urinary or bowel diversion complications, and long-term quality-of-life metrics in this surgically intense cohort. Such data are critical for care managers and payers to plan post-acute care needs, bundle payments or case management resources, and to identify opportunities to reduce costly readmissions and improve value of care.

Trials evaluating perioperative blood loss minimization and transfusion strategies for patients undergoing pelvic evisceration or radical hysterectomy: these studies test protocols such as enhanced intraoperative hemostatic techniques, restrictive transfusion thresholds, and use of cell salvage in a high-bleed, high-complexity surgical population primarily composed of patients with advanced gynecologic malignancies. The objective is to reduce intraoperative transfusions, complications, and length of stay; results inform surgeons and hospital administrators about best practices to lower complication-related costs and resource use.
Comparative effectiveness studies of different surgical approaches and perioperative care pathways in radical vulvectomy and radical hysterectomy: randomized or prospective cohort studies compare open versus minimally invasive techniques where applicable, extent of lymphadenectomy, or standardized enhanced recovery after surgery (ERAS) pathways in patients without major comorbidities (no CC/MCC). These trials address which approaches yield lower complication rates, faster functional recovery, and shorter hospitalization, providing evidence that influences DRG-level resource utilization, coding, and payer coverage decisions.
Post-discharge and survivorship outcomes research focusing on functional recovery, wound complications, and quality of life after pelvic exenteration-type procedures: longitudinal observational studies and registry-based research follow patients after discharge to quantify rates of readmission, wound breakdown, urinary or bowel diversion complications, and long-term quality-of-life metrics in this surgically intense cohort. Such data are critical for care managers and payers to plan post-acute care needs, bundle payments or case management resources, and to identify opportunities to reduce costly readmissions and improve value of care.

OpenPayer

Summary & Overview

Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy: Inpatient Reimbursement Overview

DRG 735 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes